A New Era Dawns: Suven Pharma and Cohance Lifesciences Fuse to Forge Global CDMO Powerhouse

Suven Pharmaceuticals Ltd has obtained final regulatory clearance for higher foreign investment, removing the last major impediment to its merger with Cohance Lifesciences. The Department of Pharmaceuticals has approved the company's proposal to increase overall foreign investment to more than 74%, after the recent Cabinet approval for up to ₹9,589 crore FDI, which could take foreign holding in Suven to 90.1%. The move is backed by Advent International, a global private equity colossus, and is expected to introduce world-class management practices, capacity augmentation, and employment generation.

 

With all the regulatory and shareholder approvals on board, the National Company Law Tribunal (NCLT) has approved that the merger will be effective from May 1, 2025. From this date, the merged entity will be known as Cohance Lifesciences, building a future-proof, innovation-led CDMO platform. The merged entity will have a focus on high-growth verticals such as antibody drug conjugates, oligonucleotides, and complex small molecules, and will strive to become a global specialty CDMO and API+ leader.

 

This synergistic merger is expected to deliver operating synergies, expand customer solutions, and speed up growth, making Cohance Lifesciences a global pharmaceutical industry powerhouse.

 

Source: Business Upturn, Times of India, Suven Pharmaceuticals, Press Information Bureau